Literature DB >> 27914362

An overview of the binding models of FGFR tyrosine kinases in complex with small molecule inhibitors.

Weiyan Cheng1, Mixiang Wang2, Xin Tian3, Xiaojian Zhang4.   

Abstract

The fibroblast growth factor receptor (FGFR) family receptor tyrosine kinase (RTK) includes four structurally related members, termed as FGFR1, FGFR2, FGFR3, and FGFR4. Given its intimate role in the progression of several solid tumors, excessive FGFR signaling provides an opportunity for anticancer therapy. Along with extensive pharmacological studies validating the therapeutic potential of targeting the FGFRs for cancer treatment, co-crystal structures of FGFRs/inhibitors are continuously coming up to study the mechanism of actions and explore new inhibitors. Herein, we review the reported co-crystals of FGFRs in complex with the corresponding inhibitors, main focusing our attention on the binding models and the pharmacological activities of the inhibitors.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Crystal structure; DFG-in/out; FGFR; Irreversible; Pharmacological activity; Small molecule inhibitor

Mesh:

Substances:

Year:  2016        PMID: 27914362     DOI: 10.1016/j.ejmech.2016.11.052

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  10 in total

1.  Discovery of Aminopyrazole Derivatives as Potent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR2 and 3.

Authors:  Ryan A Brawn; Andrew Cook; Kiyoyuki Omoto; Jiyuan Ke; Craig Karr; Federico Colombo; Milena Virrankoski; Sudeep Prajapati; Dominic Reynolds; David M Bolduc; Tuong-Vi Nguyen; Patricia Gee; Deanna Borrelli; Benjamin Caleb; Shihua Yao; Sean Irwin; Nicholas A Larsen; Anand Selvaraj; Xuesong Zhao; Stephanos Ioannidis
Journal:  ACS Med Chem Lett       Date:  2020-12-02       Impact factor: 4.345

2.  Discovery of a Potent Degrader for Fibroblast Growth Factor Receptor 1/2.

Authors:  Guangyan Du; Jie Jiang; Qibiao Wu; Nathaniel J Henning; Katherine A Donovan; Hong Yue; Jianwei Che; Wenchao Lu; Eric S Fischer; Nabeel Bardeesy; Tinghu Zhang; Nathanael S Gray
Journal:  Angew Chem Int Ed Engl       Date:  2021-06-14       Impact factor: 16.823

3.  Insight into resistance mechanisms of AZD4547 and E3810 to FGFR1 gatekeeper mutation via theoretical study.

Authors:  Donglou Liang; Qiaowan Chen; Yujin Guo; Ting Zhang; Wentao Guo
Journal:  Drug Des Devel Ther       Date:  2017-02-17       Impact factor: 4.162

4.  Discovery and Biological Evaluation of a Series of Pyrrolo[2,3-b]pyrazines as Novel FGFR Inhibitors.

Authors:  Yan Zhang; Hongchun Liu; Zhen Zhang; Ruifeng Wang; Tongchao Liu; Chaoyun Wang; Yuchi Ma; Jing Ai; Dongmei Zhao; Jingkang Shen; Bing Xiong
Journal:  Molecules       Date:  2017-04-05       Impact factor: 4.411

5.  Structure-Based Discovery of a Series of 5H-Pyrrolo[2,3-b]pyrazine FGFR Kinase Inhibitors.

Authors:  Alan Jiang; Qiufeng Liu; Ruifeng Wang; Peng Wei; Yang Dai; Xin Wang; Yechun Xu; Yuchi Ma; Jing Ai; Jingkang Shen; Jian Ding; Bing Xiong
Journal:  Molecules       Date:  2018-03-19       Impact factor: 4.411

Review 6.  Synthetic Heterocyclic Derivatives as Kinase Inhibitors Tested for the Treatment of Neuroblastoma.

Authors:  Francesca Musumeci; Annarita Cianciusi; Ilaria D'Agostino; Giancarlo Grossi; Anna Carbone; Silvia Schenone
Journal:  Molecules       Date:  2021-11-23       Impact factor: 4.411

7.  FGFR1 is a potential therapeutic target in neuroblastoma.

Authors:  Flora Cimmino; Annalaura Montella; Matilde Tirelli; Marianna Avitabile; Vito Alessandro Lasorsa; Feliciano Visconte; Sueva Cantalupo; Teresa Maiorino; Biagio De Angelis; Martina Morini; Aurora Castellano; Franco Locatelli; Mario Capasso; Achille Iolascon
Journal:  Cancer Cell Int       Date:  2022-04-29       Impact factor: 6.429

8.  Long-Lasting Proteinaceous Nanoformulation for Tumor Imaging and Therapy.

Authors:  Lai Zhao; Xinquan Gu; Fuquan Jiang; Bo Li; Shuang Lu; Fan Wang; Yao Sun; Kai Liu; Jingjing Li
Journal:  ACS Omega       Date:  2022-08-24

9.  Tumor-induced osteomalacia.

Authors:  Pablo Florenzano; Rachel I Gafni; Michael T Collins
Journal:  Bone Rep       Date:  2017-09-20

10.  Computational Simulation Studies on the Binding Selectivity of 1-(1H-Benzimidazol-5-yl)-5-aminopyrazoles in Complexes with FGFR1 and FGFR4.

Authors:  You-Lu Pan; Yan-Ling Liu; Jian-Zhong Chen
Journal:  Molecules       Date:  2018-03-27       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.